pacritinib (Vonjo)

Indications

• cytopenic myelofibrosis

* accelerated FDA approval based on spleen volume reduction

Contraindications

• no better than placebo in patients with severe Covid-19

Dosage

• 200 mg BID

capsules 100 mg

Pharmacokinetics

• metabolized by CYP3A4

Adverse effects

• > 20%
  • diarrhea, thrombocytopenia, nausea, anemia, peripheral edema

Drug interactions

• CYP3A4 inhibitors may increase toxicity
• CYP3A4 inducers may decrease efficacy

Mechanism of action

• inhibits JAK2 & IRAK1
• minimal JAK1 inhibition

More general terms

• small inhibitory antineoplastic agent (ib drug)
• hematologic agent

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=46216796
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=73354318
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=67443473
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=46216795